Prostatic Leiomyosarcoma: The Case for Combined Modality Therapy
Author Information
Author(s): Salah El-Sharkawi, Keith Vaughton
Primary Institution: Singleton Hospital, Swansea & Morriston Hospital, Swansea, UK
Hypothesis
Is combined modality therapy the best initial treatment for prostatic leiomyosarcoma?
Conclusion
Combined modality therapy may be a more effective initial treatment for prostatic leiomyosarcoma than radical surgery alone.
Supporting Evidence
- Prostatic leiomyosarcoma is a rare and aggressive cancer with poor prognosis.
- The patient initially responded well to treatment but later developed metastases.
- Combined modality therapy may improve outcomes compared to radical surgery alone.
Takeaway
A 65-year-old man with a rare prostate cancer was treated with surgery and radiation, but unfortunately, he later developed cancer in his lungs and brain.
Methodology
The patient underwent surgery and radiotherapy, followed by chemotherapy for palliation.
Limitations
The rarity of prostatic leiomyosarcoma makes it difficult to draw broad conclusions from a single case.
Participant Demographics
65-year-old male patient.
Want to read the original?
Access the complete publication on the publisher's website